Last updated: August 15, 2026
Celgene Corporation v. Synthon Pharmaceuticals, Inc., No. 2:18-cv-10775, was an ANDA patent-infringement action in the U.S. District Court for the District of New Jersey concerning Synthon's proposed generic version of Pomalyst, whose active ingredient is pomalidomide. Celgene asserted patents covering pomalidomide and its use in treating multiple myeloma. The case was resolved without a reported trial judgment, and publicly available materials do not disclose the commercial terms of the parties' resolution. [1]
What drug was at issue in Celgene v. Synthon?
The litigation concerned Pomalyst capsules, an oral immunomodulatory drug approved by the FDA for multiple myeloma and Kaposi sarcoma indications. Celgene developed and commercialized Pomalyst before its acquisition by Bristol Myers Squibb in 2019. [2]
| Item |
Detail |
| Brand |
Pomalyst |
| Active ingredient |
Pomalidomide |
| Dosage form |
Oral capsules |
| Reference sponsor |
Celgene Corporation |
| Current parent company |
Bristol Myers Squibb |
| Regulatory pathway |
Abbreviated New Drug Application |
| Defendant |
Synthon Pharmaceuticals, Inc. |
| Court |
U.S. District Court for the District of New Jersey |
| Case number |
2:18-cv-10775 |
| Litigation type |
Hatch-Waxman patent infringement |
| Primary risk |
Generic pomalidomide entry |
Synthon's ANDA filing triggered Celgene's patent litigation after Synthon made Paragraph IV certifications challenging patents listed for Pomalyst in the FDA's Orange Book. Under the Hatch-Waxman Act, the filing of an infringement action within 45 days of receiving a Paragraph IV notice generally creates an automatic 30-month stay of FDA approval. [3]
What patents protected Pomalyst?
Pomalyst's patent estate included composition, treatment-method, dosing, and risk-management-related intellectual property. The principal protection relevant to generic entry was the patent covering pomalidomide itself and later-expiring patents covering therapeutic use.
Pomalidomide composition patent
U.S. Patent No. 8,198,262 was directed to pomalidomide and related compositions. The patent was assigned to Celgene and had an expiration date in 2027, subject to any applicable patent-term adjustment or pediatric exclusivity. [4]
The composition patent presented the principal obstacle to an ANDA applicant seeking approval for the active ingredient in Pomalyst. A successful validity challenge or a noninfringement position could remove that barrier, but the patent's claims were central to Celgene's generic-entry strategy.
Method-of-use patents
Celgene also held patents covering the use of pomalidomide in multiple myeloma and related treatment regimens. U.S. Patent No. 8,735,428 is associated with methods for treating multiple myeloma using pomalidomide. Its expiration date extended beyond the composition patent, into 2030, before any applicable extension. [5]
Method-of-use patents can remain commercially important even when a generic applicant seeks approval for a narrower indication. A Paragraph IV certification can challenge the patent directly, while a Section viii statement may attempt to carve out the patented indication from the generic label.
Orange Book listing issues
The Orange Book status of Pomalyst patents must be evaluated by strength of claim, expiration date, and whether each patent was listed for the particular dosage form and approved labeling. Patent listings do not establish validity. They identify patents that a generic applicant must address in its ANDA certification.
| Patent category |
Commercial purpose |
Generic-entry significance |
| Composition |
Protects pomalidomide and related compositions |
Blocks approval if valid and infringed |
| Method of use |
Protects multiple-myeloma treatment regimens |
May support full or partial label exclusion |
| Dosing regimen |
Protects administration schedules or patient-selection criteria |
Depends on claim scope and label content |
| Risk-management system |
Protects controlled-distribution implementation |
Usually less important than active-ingredient claims |
When did the Pomalyst exclusivity period end?
Pomalyst's FDA regulatory exclusivity and patent exclusivity were separate.
The drug received FDA approval in 2013. New Chemical Entity exclusivity generally lasted five years from approval, subject to the timing of the ANDA filing and any applicable statutory provisions. That regulatory exclusivity period did not determine the ultimate generic launch date because Celgene's later-expiring patents remained the principal barrier. [2]
The relevant commercial timeline was therefore driven by patent expiration and settlement rights rather than by FDA NCE exclusivity.
| Event |
Approximate timing |
| Pomalyst FDA approval |
2013 |
| NCE exclusivity |
Approximately 2018 |
| Synthon ANDA litigation |
2018 |
| Composition-patent barrier |
Through approximately 2027 |
| Later method-of-use protection |
Through approximately 2030 |
| BMS ownership of Pomalyst |
From 2019 |
Patent-term adjustment, pediatric exclusivity, terminal disclaimers, and any settlement license can change the effective launch date. A patent expiration date alone does not establish when a particular generic can enter.
What Paragraph IV challenge did Synthon make?
Synthon's ANDA certification challenged Celgene's Orange Book-listed Pomalyst patents. The challenge likely placed validity, enforceability, and infringement at issue under the Hatch-Waxman framework.
The principal legal theories in a Pomalyst ANDA case would include:
- Invalidity based on anticipation or obviousness.
- Noninfringement based on the ANDA's proposed formulation, labeling, or use.
- Lack of enforceability based on inequitable conduct or statutory defects.
- A carve-out of patented methods from the proposed label.
- Disputes over whether the asserted claims were properly listed in the Orange Book.
The case was not a conventional commercial patent dispute. Celgene's objective was to prevent FDA approval or commercial launch of Synthon's ANDA product until the asserted patents expired or a negotiated license became effective.
What was the litigation outcome?
The public litigation record does not show a reported trial verdict or Federal Circuit decision resolving the validity or infringement of the asserted Pomalyst patents. The case was resolved without a publicly reported merits judgment. The commercial terms of the resolution were not disclosed in the public docket materials.
That outcome is consistent with the standard pattern for pharmaceutical ANDA litigation. Brand and generic companies frequently resolve Hatch-Waxman cases through confidential settlement agreements that establish a future launch date, subject to regulatory and patent conditions.
The absence of a merits decision means the case did not produce binding judicial findings on:
- The validity of Celgene's Pomalyst patents.
- Whether Synthon's proposed product infringed the asserted claims.
- The scope of any permissible label carve-out.
- The enforceability of the asserted patents.
- The precise date on which Synthon could launch.
Did Celgene and Synthon sign a settlement agreement?
The parties' resolution was not accompanied by publicly available commercial terms identifying a launch date, royalty structure, supply arrangement, or license scope. Public dismissal papers in pharmaceutical patent cases commonly state that the action is being terminated pursuant to a settlement while withholding the agreement itself.
The absence of disclosed terms limits the ability to determine whether the settlement provided:
- A fixed launch date.
- An earlier launch tied to third-party generic entry.
- An authorized-generic arrangement.
- A royalty-bearing license.
- A supply agreement.
- A license limited to certain strengths or indications.
- Restrictions on sublicensing or distribution.
For valuation purposes, the key unanswered commercial variable is whether Synthon received an entry date before expiration of the principal Pomalyst patents. A settlement can reduce litigation risk for both parties while preserving substantial patent-based revenue through delayed generic entry.
What patent litigation affected Pomalyst generic entry?
Celgene pursued multiple ANDA cases involving Pomalyst and other applicants. These cases formed part of a broader generic challenge to Celgene's immunomodulatory-drug portfolio, including Revlimid and Thalomid.
Comparison with Revlimid
| Issue |
Pomalyst |
Revlimid |
| Active ingredient |
Pomalidomide |
Lenalidomide |
| Primary indication |
Multiple myeloma |
Multiple myeloma and other blood cancers |
| Commercial scale |
Smaller than Revlimid |
Celgene's largest product |
| Generic litigation |
Composition and method patents |
Extensive composition, method, dosing, and risk-management claims |
| Generic-entry sensitivity |
High due to oncology pricing |
Very high due to major revenue exposure |
| Corporate owner |
Bristol Myers Squibb |
Bristol Myers Squibb |
Revlimid generated substantially greater revenue than Pomalyst, making its patent settlements and launch restrictions more commercially significant. Pomalyst nevertheless had a durable patent estate and high-value oncology pricing.
How strong was Celgene's Pomalyst patent estate?
Celgene's Pomalyst estate had moderate-to-strong defensive value because it combined an active-ingredient patent with later method-of-use protection. The composition patent was the most commercially valuable asset. If enforceable and infringed, it could delay approval of a generic product covering the same active ingredient.
The estate's principal vulnerabilities were typical of small-molecule oncology products:
- Prior-art challenges to the claimed chemical structure.
- Obviousness challenges based on related immunomodulatory compounds.
- Written-description and enablement challenges.
- Label-based noninfringement arguments.
- Section viii carve-outs for patented uses.
- Orange Book listing disputes.
- Potential limitations from narrow claim construction.
The estate was stronger than a single method-of-use patent portfolio because Celgene had layered protection. It was weaker than a portfolio supported by an unexpired composition patent, multiple independent formulation patents, and enforceable manufacturing claims.
What generic launch risks existed for Synthon?
Synthon faced four principal launch risks.
Regulatory approval risk
The FDA could not approve the ANDA during the statutory litigation stay unless the litigation was resolved, the patents expired, or a court entered an earlier judgment permitting approval. [3]
Patent-infringement risk
A commercial launch before resolution of the asserted patents could expose Synthon to damages, injunctive relief, and a potential loss of market access.
Label risk
A carve-out strategy could reduce infringement exposure but might prevent Synthon from fully matching Pomalyst's approved label. That limitation can reduce substitution, physician adoption, and pharmacy dispensing.
Commercial risk
Pomalidomide is an oncology product distributed through specialized channels and subject to risk-management controls. A generic entrant would need to match regulatory, distribution, reimbursement, and patient-access requirements, not merely obtain FDA approval.
What revenue exposure did the litigation create?
The case created asymmetric economic exposure. Celgene risked erosion of Pomalyst revenue if Synthon entered before the practical end of patent protection. Synthon faced substantial development and litigation costs, but a successful launch could produce high margins because generic competition in specialty oncology can initially be limited.
The value of the case depended on:
- Pomalyst sales at the settlement date.
- The number of approved generic strengths.
- The number of competing ANDA applicants.
- The effective launch date.
- Whether entry was exclusive or concurrent.
- The scope of any licensed indication.
- The rate of price erosion after generic entry.
- Pomalyst's role in combination regimens for multiple myeloma.
Bristol Myers Squibb's acquisition of Celgene transferred the economic benefit and litigation risk to BMS. Pomalyst remained part of BMS's hematology portfolio alongside Revlimid and other oncology products. [6]
Does the case create biosimilar risk?
No. Pomalyst is a small-molecule drug, so the relevant competitive pathway is an ANDA under the Hatch-Waxman Act, not a biosimilar application under the Public Health Service Act.
The competitive risks are generic substitution, Paragraph IV litigation, authorized generics, and settlement-controlled entry. Biosimilar litigation concepts do not apply to pomalidomide.
What is the geographic scope of the patent protection?
The case concerned U.S. patent rights and FDA approval. Celgene's U.S. patents did not directly determine generic entry in Europe, Canada, Japan, or other markets. Each jurisdiction required separate patent, regulatory, and settlement analysis.
The United States remained commercially important because:
- The FDA Orange Book controls U.S. ANDA patent certifications.
- U.S. Paragraph IV litigation can delay approval.
- U.S. oncology pricing is materially higher than in many other markets.
- U.S. settlement terms may restrict only U.S. commercialization.
Key Takeaways
- Celgene v. Synthon was a Hatch-Waxman case involving Synthon's proposed generic Pomalyst product.
- The active ingredient was pomalidomide.
- Celgene's principal protection included U.S. Patent No. 8,198,262 and later method-of-use protection, including U.S. Patent No. 8,735,428.
- The litigation did not produce a reported trial judgment or appellate merits decision.
- The parties' commercial resolution was not publicly disclosed in detail.
- The case concerned generic risk, not biosimilar risk.
- The composition patent and later treatment patents created layered protection extending beyond FDA regulatory exclusivity.
- The commercial value of the settlement depends mainly on the generic launch date and the number of competing entrants.
- BMS assumed Celgene's economic interest in Pomalyst after acquiring Celgene.
- Any final entry analysis must distinguish patent expiration from the effective launch date created by settlement, regulatory approval, and market competition.
FAQs
What is the case number for Celgene's Pomalyst lawsuit against Synthon?
The case number is 2:18-cv-10775 in the U.S. District Court for the District of New Jersey.
Was Synthon's Pomalyst product approved by the FDA?
The litigation docket does not establish a reported FDA approval date or commercial launch date for Synthon's product.
Is pomalidomide protected by a composition patent?
Yes. Celgene held composition protection for pomalidomide, including U.S. Patent No. 8,198,262, with protection extending into 2027 before applicable adjustments or extensions.
Can a generic company sell pomalidomide for only some indications?
Yes. An ANDA applicant may pursue a Section viii label carve-out for a patented method of use, subject to the FDA's approval requirements and the scope of the remaining label.
Did the Synthon case establish that Celgene's Pomalyst patents were valid?
No reported merits decision in the case established the validity or infringement of the asserted Pomalyst patents.
References
-
U.S. District Court for the District of New Jersey. (2018). Celgene Corporation v. Synthon Pharmaceuticals, Inc., No. 2:18-cv-10775. PACER/Court docket.
-
U.S. Food and Drug Administration. (2013). Pomalyst (pomalidomide) prescribing information. FDA.
-
Hatch-Waxman Act, 21 U.S.C. § 355(j)(5)(B)(iii).
-
U.S. Patent and Trademark Office. (2002). U.S. Patent No. 8,198,262, Pomalidomide and related compositions. USPTO Patent Center.
-
U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,735,428, Methods for treating multiple myeloma. USPTO Patent Center.
-
Bristol Myers Squibb. (2019). Bristol Myers Squibb completes acquisition of Celgene. Company release.
